Literature DB >> 26931749

Extreme Sport/Adventure Activity Correlates in Gynecologic Cancer Survivors.

Jennifer J Crawford1, Jeff K Vallance2, Nicholas L Holt1, Kerry S Courneya3.   

Abstract

OBJECTIVE: We examined the demographic, medical and behavioral correlates of participation and interest in extreme sport/adventure activities (ESAA) in gynecologic cancer survivors.
METHODS: A random sample of 621 gynecologic cancer survivors in Alberta, Canada, completed a mailed self-report questionnaire assessing medical, demographic, and behavioral variables and participation and interest in ESAA.
RESULTS: Multivariate analyses revealed that gynecologic cancer survivors were more likely to participate in ESAA if they met aerobic exercise guidelines (OR=1.75 [95%CI:1.02-2.99]), had better general health (OR=1.71 [95%CI: 1.01-2.90]), had cervical or ovarian cancer (OR=1.95 [95%CI:0.97-3.93]), were employed (OR=1.71 [95%CI:0.95-3.08]), and were of healthy weight (OR=1.58 [95%CI:0.93-2.68]). Moreover, gynecologic cancer survivors were more likely to be interested in trying an ESAA if they had cervical or ovarian cancer (OR=1.76 [95%CI:0.94-3.27]) and were meeting the strength exercise guidelines (OR=1.68 [95%CI:0.95-2.98]).
CONCLUSIONS: Medical, demographic, and behavioral variables correlate with participation and interest in ESAA in gynecologic cancer survivors. The pattern of correlates suggests that gynecologic cancer survivors are more likely to participate in ESSA if they have the physical capability and financial resources. Interventions to promote ESAA in gynecologic cancer survivors need to address these 2 key barriers.

Entities:  

Mesh:

Year:  2016        PMID: 26931749     DOI: 10.5993/AJHB.40.2.2

Source DB:  PubMed          Journal:  Am J Health Behav        ISSN: 1087-3244


  1 in total

1.  A new paradigm for examining the correlates of aerobic, strength, and combined exercise: an application to gynecologic cancer survivors.

Authors:  Jennifer J Crawford; Nicholas L Holt; Jeff K Vallance; Kerry S Courneya
Journal:  Support Care Cancer       Date:  2016-03-28       Impact factor: 3.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.